Results 131 to 140 of about 3,217 (222)

Leveraging natural language processing to aggregate field safety notices of medical devices across the EU. [PDF]

NPJ Digit Med
Ren Y, Caiani EG.
europepmc   +1 more source

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma. [PDF]

Blood Cancer J
Jurgens E, Shekarkhand T, Rueda C, Nemirovsky D, Derkach A, Firestone RS, Miller K, Costa BA, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Hamadeh I, Giralt SA, Shah GL, Landau HJ, Scordo M, Usmani SZ, Mailankody S, Shahid Z.   +24 more
europepmc   +1 more source

The Implementation of Mashups Web to Integrate Students Data and Service Announcement in a University Website

, 2013
Fransisko EkoSanaky, Eko Sediyono, Irwan Sembiring   +2 more
openalex   +1 more source

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. [PDF]

Oncologist
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O.   +34 more
europepmc   +1 more source

Mail Plugin for IBM Mashup Center

, 2010
Pinaki Mitra, Girish Sundaram, Senthil Kumar G, Vishal Kurup   +3 more
openalex   +2 more sources

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma. [PDF]

Int J Clin Oncol
Kikuchi E, Van der Heijden MS, Valderrama BP, Gupta S, Bedke J, Shin SJ, Li JR, Guo J, Danchaivijitr P, Kanesvaran R, Park SH, Su WP, Kandori S, Bae WK, Wong A, Gorla S, Bavle A, Yu X, Lu YT, Powles T.   +19 more
europepmc   +1 more source

Mashup indices of development

, 2010
Martin Ravallion
openalex   +2 more sources

The Heartline Experience: Achieving Long-Term Participant Engagement in Digital Health Technology Trials. [PDF]

JACC Adv
Nikolovski J, Navar AM, Steinhubl S, Baca-Motes K, Curtis AB, Peterson ED, Lakkireddy D, Tarino M, Juan S, Damaraju CRV, Wentworth D, Wildenhaus K, Patel M, Tavakoli C, Gibson CM, Spertus JA, Heartline Steering Committee.   +16 more
europepmc   +1 more source

Artificial intelligence for algorithmic trading digital assets: evidence from the Counter-Strike 2 skin market. [PDF]

Front Artif Intell
Guede-Fernández F, Wagle Y, Dias P, Giordano AP, Henriques L, Costa G, Azevedo S.   +6 more
europepmc   +1 more source

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma. [PDF]

Blood Cancer J
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa BA, Lesokhin A, Tan CR, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S, Mailankody S, Hashmi H.   +22 more
europepmc   +1 more source